I see, that makes sense! If everything went perfectly, from this early stage research to clinical trials to broad deployment, ~5% (most but not all of the 7% chronic respiratory disease) is a reasonable estimate. It could theoretically be higher if there are e.g. positive effects on cardiovascular disease from healthy lungs, but those kinds of nebulous benefits are hard to predict.
To be clear though I'm sure you know, like all preclinical research it is many millions of dollars and very high chance of failure away from hitting that 5%.